The GLP is committed to full transparency. Download and review our Annual Report.

Inside the quest to find a place in modern medicine for magic mushrooms as a treatment for depression, other mental illnesses

| | July 10, 2019

Today, with a net worth of roughly $400 million accrued through various enterprises, [German financier Christian] Angermayer is one of the driving forces behind the movement to turn long-shunned psychoactive substances, like the psilocybin derived from so-called magic mushrooms, into approved medications for depression and other mental illnesses. Though he still resolutely won’t touch even a drop of alcohol, he has banded together a team of like-minded entrepreneurs — including Silicon Valley billionaire Peter Thiel — to invest in a handful of startups focused on developing psychedelics. 

Perhaps the most closely watched is Compass Pathways, which has patented a method to develop psilocybin in a laboratory, so it doesn’t need to be extracted from mushrooms. The company has quietly gobbled up intellectual property related to psychedelic manufacturing. And, importantly, it has won Food and Drug Administration approval to run clinical trials testing psilocybin in patients with treatment-resistant depression.

“Even if it takes just a single dose of psilocybin to treat depression — and I’d be very, very happy if that’s the case — the medical unmet need is huge,” Angermayer said. “The market is growing, for better or for worse.”

Read full, original post: The psychedelics evangelist: A German financier wants to turn magic mushrooms into modern medicine

Related article:  5 things to consider with direct-to-consumer health products
The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend